PMS17 Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in kazakhstan

Simple item page
dc.contributor.authorBektur, C.
dc.contributor.authorNurgozhin, T.
dc.creatorC., Bektur
dc.date.accessioned2017-12-13T09:25:28Z
dc.date.available2017-12-13T09:25:28Z
dc.date.issued2014-11-01
dc.description.abstractA phase III clinical trial demonstrated the advantage of denosumab over zoledronic acid(ZA) in delaying the first on-study and subsequent skeletal-related events(SREs) in patients with prostate cancer(PC). Recently, generic ZA became available. The purpose of this study was to examine the cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani patients with PC.
dc.identifierDOI:10.1016/j.jval.2014.08.333
dc.identifier.citationC. Bektur, T. Nurgozhin, PMS17 - Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in Kazakhstan, In Value in Health, Volume 17, Issue 7, 2014, Pages A773-A774
dc.identifier.issn10983015
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1098301514022633
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/2874
dc.relation.ispartofValue in Health
dc.rights.licenseCopyright © 2014 Published by Elsevier Inc.
dc.titlePMS17 Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in kazakhstan
dc.typeArticle
elsevier.aggregationtypeJournal
elsevier.coverdate2014-11-01
elsevier.coverdisplaydateNovember 2014
elsevier.endingpageA774
elsevier.identifier.doi10.1016/j.jval.2014.08.333
elsevier.identifier.eid1-s2.0-S1098301514022633
elsevier.identifier.piiS1098-3015(14)02263-3
elsevier.issue.identifier7
elsevier.openaccess1
elsevier.openaccessarticletrue
elsevier.openaccessuserlicensehttp://www.elsevier.com/open-access/userlicense/1.0/
elsevier.openarchivearticletrue
elsevier.startingpageA773
elsevier.volume17

Files

Collections

Center for Life Sciences